Cures Within Reach

Cures Within Reach (CWR) is a US-based philanthropic leader that improves patient quality and length of life by leveraging the speed, safety and cost-effectiveness of testing already approved therapies for new indications that serve philanthropic and/or commercial uses, driving more treatments to more patients more quickly. The ongoing COVID19 pandemic shined a spotlight on what CWR's known for over a decade: clinical repurposing trials are a globally accepted way to quickly bring possible treatments to patients. CWR focuses on first-in-human or proof-of-concept clinical repurposing trials that, if successful, catalyze follow-on funding needed to continue the research, support reputable publication allowing clinicians to make their own decisions with their patients, and building evidence for regulatory approval by the FDA or other agencies. CWR is institution-agnostic, geography-agnostic and disease-agnostic, allowing its neutral and conflict-free process to fund both research institutions and pre-commercial small businesses focused on finding treatments for patients with unmet medical needs. Launched in 2005 and focused solely on repurposing since 2008 with a 12+ year track record, its disease-agnostic funding of over $7 million to over 95 projects has helped to catalyze more than $67 million in follow-on funding – leveraging nearly $10 in new funding for each $1 that CWR invested.